TY - JOUR T1 - A Continuously Active Antimicrobial Coating effective against Human Coronavirus 229E JF - medRxiv DO - 10.1101/2020.05.10.20097329 SP - 2020.05.10.20097329 AU - Luisa A. Ikner AU - Jason R. Torrey AU - Patricia M. Gundy AU - Charles P. Gerba Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/13/2020.05.10.20097329.abstract N2 - The disinfection of high-contact surfaces is seen as an infection control practice to prevent the spread of pathogens by fomites. Unfortunately, recontamination of these surfaces can occur any time after the use of common disinfectants. We recently reported on a novel continuously active antimicrobial coating which was shown to reduce the spread of healthcare acquired infections in hospitals. We evaluated a modified coating that demonstrated a residual efficacy against viruses. The coated surfaces were found to be effective against human coronavirus (HCoV) 229E, reducing the concentration of these viruses by greater than 90% in 10 minutes and by greater than 99.9% after two hours of contact. The coating formulation when tested in suspension yielded a greater than 99.99% reduction of HCoV 229E within ten minutes of contact. This outcome presents an opportunity for controlling the transmission of COVID-19 from contaminated fomites.Competing Interest StatementThis project was funded by Allied Biosciences to the University of Arizona, whose researchers participated in the study design. The conduct of the study, analysis, and presentation of the results as well as the decision to publish were solely determined by the authors without influence by the funding source.Funding StatementThis project was funded by a grant from Allied Biosciences to the University of Arizona,Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and calculations for each experiment can be provided ER -